Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication

International Journal of Hematology

Volumn 84, Issue 4, 2006, Pages 328-336

  Abe, Akihiro ^a   Kiyoi, Hitoshi ^a   Ninomiya, Manabu ^a   Yamazaki, Tomio ^b   Murase, Takuhei ^c   Ozeki, Kazutaka ^a   Suzuki, Momoko ^a   Hayakawa, Fumihiko ^a   Katsumi, Akira ^a   Emi, Nobuhiko ^d   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c Nishio City Hospital   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

FLT3; Kinase inhibitors; Myelomonocytic leukemia cell; Stroma cell; Stroma dependent

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; FLT3 LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT5 PROTEIN; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN;

ACUTE MYELOMONOCYTIC LEUKEMIA; ARTICLE; CELL PROLIFERATION; CELL STRAIN NAMO 2; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; KARYOTYPING; LEUKEMIA CELL LINE; NUDE MOUSE; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; EXPERIMENTAL NEOPLASM; GENETICS; HOMOZYGOTE; MOUSE; MYELOMONOCYTIC LEUKEMIA; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; STROMA CELL; TANDEM REPEAT; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; FMS-LIKE TYROSINE KINASE 3; HOMOZYGOTE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STROMAL CELLS; TANDEM REPEAT SEQUENCES; TRANSPLANTATION, HETEROLOGOUS;

EID: 34247268465     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06056     Document Type: Article

References (31)

1. Bentley SA. Close range celiceli interaction required for stem cell maintenance in continuous bone marrow culture. Exp Hematol. 1981;9:308-312.
2. Dorshkind K. Regulation of hemopoiesis by bone marrow stromal cells and their products. Annu Rev Immunol. 1990;8:111-137.
3. Rood PM, Dercksen MW, Cazemier H, et al. E-selectin and very late activation antigen-4 mediate adhesion of hematopoietic progenitor cells to bone marrow endothelium. Ann Hematol. 2000;79:477-484.
4. + stem cell adhesion. Cell Biol Int. 1998;22:641-648.
5. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841-846.
6. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836-841.
7. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118:149-161.
8. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10:64-71.
9. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9:1158-1165.
10. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
11. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
12. Minami Y, Kiyoi H, Yamamoto Y, et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia. 2002;16:1535-1540.
13. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609.
14. Kiyoi H, Yanada M, Ozekia K. Clinical significance of FLT3 in leukemia. Int J Hematol. 2005;82:85-92.
15. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003;17:120-124.
16. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood. 2005;105:4792-4799.
17. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia. 1997;11:1447-1452.
18. Ono R, Nakajima H, Ozaki K, et al. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest. 2005;115:919-929.
19. Ninomiya M, Abe A, Yokozawa T, et al. Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene. Cancer Genet Cytogenet. 2006;169:1-11.
20. Takeo T, Ogura M, Okumura M, et al. New xenografts of human megakaryoblastic cell line (MEG-01) for evaluating anti-tumor agents. Leukemia. 1993;7:1268-1274.
21. Kanie T, Abe A, Matsuda T, et al. TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways. Leukemia. 2004;18:548-555.
22. Kovalenko M, Gazit A, Bohmer A, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994;54:6106-6114.
23. Tse KF, Novelli E, Civin CI, Bohmer FD, Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. 2001;15:1001-1010.
24. Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103:1901-1908.
25. Marcucci G, Strout MP, Bloomfield CD, Caligiuri MA. Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. Cancer Res. 1998;58:790-793.
26. Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science. 1994;265:1098-1101.
27. Kawano Y, Kobune M, Yamaguchi M, et al. Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells. Blood. 2003;101:532-540.
28. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885-3891.
29. Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 2003;101:1494-1504.
30. Levis M, Small D. FLT3 tyrosine kinase inhibitors. Int J Hematol. 2005;82:100-107.
31. Robinson LJ, Xue J, Corey SJ. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 2005;33:469-479.